Reference : Pharmaco-economie des medicaments hypolipidemiants: analyse des facteurs influencant ...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Pharmaco-economie des medicaments hypolipidemiants: analyse des facteurs influencant le rapport cout/efficacite.
[en] Pharmaco-economics of hypolipidemic agents: analysis of factors influencing the cost-effectiveness relation
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Revue Médicale de Liège
CHU de Liège
Yes (verified by ORBi)
[en] Adult ; Aged ; Anticholesteremic Agents/economics/therapeutic use ; Antilipemic Agents/economics/therapeutic use ; Coronary Disease/prevention & control ; Cost-Benefit Analysis ; Drug Costs ; Economics, Pharmaceutical ; Female ; Heart Diseases/prevention & control ; Humans ; Hypercholesterolemia/drug therapy/prevention & control ; Male ; Middle Aged ; Naphthalenes/economics/therapeutic use ; Risk Factors
[en] The demonstration that stains reduce the risk of cardiovascular diseases, in both secondary and primary prevention trials, led to the recent publication of sophisticated pharmaco-economical studies. A lot of factors may influence the cost-effectiveness ratio of the pharmacological intervention, especially the mode of calculation of various costs, the initial level of cardiovascular risk of the patients and the medico-economical particularities of each country. What so ever, available studies appear to justify the use of statins in secondary prevention, i.e. in coronary patients, even those with only a moderate hypercholesterolaemia, and, in primary prevention, i.e in hypercholesterolaemia individuals with obvious high risk of cardiovascular disease.

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.